Xencor, Inc.

Biomunex Pharmaceuticals

Eugene Alexander Zhukovsky

John R Desjarlais

Matthew J Bernett

Gregory Alan Lazar

Sher Bahadur Karki

Seung Yup Chu

Erik Weiking Pong

John O Richards

Olivier Leger

Richard J Morse

Adam Read Thomason

The present invention relates to a mutant polypeptide linker for preparing multispecific antibodies, multispecific antibodies, and methods for producing multispecific antibodies.

Polypeptide linker for preparing multispecific antibodies

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Optimized antibodies that target CD19

The invention relates to multispecific antibody constructs comprising Fab fragments having a particular set of mutations at the interface of the CH1 and CL domains, the mutations preventing heavy chain/light chain mispairing.

Stable multispecific antibodies

The present invention relates to a bispecific molecule comprising at least one anti-CD38 domain and at leak one anti-PD-L1 domain, which are capable of simultaneous binding to CD38 and PD-L1 antigens, respectively.

Binding molecules to CD38 and PD-L1

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells

Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

The invention relates to novel proteins with BAFF dominant negative antagonist, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of BAFF or APRIL-related disorders.

Growing community of inventors

West Hollywood, CA, United States of America

Eugene Alexander Zhukovsky